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Abstract
Background: Haptocorrin is a vitamin B12-binding protein present in high amounts in different body fluids
including human milk. Haptocorrin has previously been shown to inhibit the growth of specific E. coli strains, and
the aim of the present study was to elucidate whether the antibacterial properties of this protein may exert a
general defense against pathogens and/or affect the composition of the developing microbiota in the
gastrointestinal tracts of breastfed infants.
Findings: The present work was the first systematic study of the effect of haptocorrin on bacterial growth, and
included 34 commensal and pathogenic bacteria to which infants are likely to be exposed. Well-diffusion assays
addressing antibacterial effects were performed with human milk, haptocorrin-free human milk, porcine holo-
haptocorrin (saturated with B-12) and human apo-haptocorrin (unsaturated). Human milk inhibited the growth of
S. thermophilus and the pathogenic strains L. monocytogenes LO28, L. monocytogenes 4446 and L. monocytogenes
7291, but the inhibition could not be ascribed to haptocorrin. Human apo-haptocorrin inhibited the growth of only
a single bacterial strain (Bifidobacterium breve), while porcine holo-haptocorrin did not show any inhibitory effect.
Conclusions: Our results suggest that haptocorrin does not have a general antibacterial activity, and thereby
contradict the existing hypothesis implicating such an effect. The study contributes to the knowledge on the
potential impact of breastfeeding on the establishment of a healthy microbiota in infants.
Findings
Background and hypothesis
Haptocorrin (previously named transcobalamin I and III,
and R-binder) is a glycoprotein, which is present in
human milk in relatively large amounts [1,2]. It is charac-
terized by its ability to bind vitamin B12 and other corri-
noids [3], and exists in two forms in human milk; apo-
haptocorrin, which is unsaturated with vitamin B12, and
holo-haptocorrin, which is saturated with vitamin B12
[4]. Human milk contains a much higher concentration
of apo-haptocorrin than of holo-haptocorrin [1,2], but
the role for the high amount of apo-haptocorrin in
human milk is unknown. Furthermore, the function of
haptocorrin in different body fluids, i.e. secreted from
exocrine glands or released by erythrocytes and leuco-
cytes, remains unknown. However, the current concept is
that haptocorrin in adults is responsible for transporting
dietary vitamin B12 through the stomach to the intestine.
Haptocorrin is believed to be degraded by the intestinal
enzymes and the vitamin B12 released from the protein
is subsequently bound to intrinsic factor and absorbed in
the distal part of ileum [5]. It has been proposed that
haptocorrin contributes to the transport and absorption
of vitamin B12 in infants while the gastric secretion of IF
is not sufficiently developed [6]. On the other hand, the
high amount of apo-haptocorrin in human milk has lead
to suggestions that haptocorrin, by withholding vitamin
B12, exhibits antimicrobial effects in the intestine and
thereby potentially protects the infant against pathogenic
bacteria [1,7]. Additionally, we speculate that an antibac-
terial (protective) function of haptocorrin could explain
its presence in various body fluids.
* Correspondence: trli@food.dtu.dk
† Contributed equally
1National Food Institute, Mørkhøj Bygade 19, Technical University of
Denmark, DK-2860 Søborg, Denmark
Full list of author information is available at the end of the article
Jensen et al. BMC Research Notes 2011, 4:208
http://www.biomedcentral.com/1756-0500/4/208
© 2011 Licht et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.The possible effect of haptocorrin on bacteria has
been discussed since the late 1970’s [1,7-9]. However,
only a very limited number of studies addressing such
an effect have been performed, and these studies have
focused on the effect of haptocorrin on E. coli [8-10].
Samson et al demonstrated that apo-haptocorrin,
derived from human milk, inhibits the growth of the
vitamin B12-dependent E. coli N.C.I.B. 8134 [8]. This
effect was shown to be diminished by pretreatment with
trypsin [9]. The gastrointestinal tract of infants differs
from the adult gut in terms of higher pH and lower
trypsin activity [11-14], thus haptocorrin may still be
functional in the upper part of the intestine during
infancy. Indeed, it has been demonstrated that porcine
haptocorrin is not degraded in vitro when subjected to
an environment simulating the gastrointestinal tract of
infants [10].
Previous studies have shown that both apo-and holo-
haptocorrin inhibits the growth of a single enteropatho-
genic E. coli O127 strain (EPEC) [10], thereby suggesting
that the haptocorrin moity rather than its ability to bind
cobalamin inhibits the growth of pathogens [15]. How-
ever, to date no study has systematically investigated the
effect of haptocorrin (saturated or unsaturated) on a
panel of bacteria.
Recently, the importance of the first colonizing bac-
teria in infants for the development of a healthy
immune system has been highlighted [16,17], and it is
known that the microbiota of breastfed infants differ
from that of formula fed infants [18]. We hypothesized
that haptocorrin from human milk, by inhibiting the
growth of certain bacteria and thereby favoring the
growth of other bacteria, may influence the initial colo-
nization in breastfed infants. We therefore performed
the first systematical study of the effect of haptocorrin
on a panel of 34 commensal and pathogenic bacteria to
which infants may be exposed, and conclude that
human unsaturated haptocorrin had no general antibac-
terial effect, but was seen to inhibit the growth of Bifi-
dobacterium breve, which is commonly found in the
intestinal tract of neonates.
Materials and methods
Biochemical methods
The concentration of vitamin B12, in BHI and MRS
media, was analyzed employing the Cobas 6000 E
immunoassay system and the analytical kit supplied by
the manufacturer (Roche). Unsaturated vitamin B12
binding capacity (UB12BC) in BHI and MRS was mea-
sured as described previously [19]. The vitamin B12
content and the UB12BC of Clostridium difficile media
were not measured due to lack of the liquid form of the
specific agar media used in the well-diffusion assay.
Human milk
Human donor milk, collected at Randers Hospital,
Denmark was centrifuged at 10,000 g, 4°C, 15 min. It
contained 70 nM haptocorrin and 0.85 nM cobalamin
(holo-haptocorrin).
Haptocorrin-free human milk was prepared by affinity
purification using polyclonal antibodies against human
haptocorrin [3] covalently linked to protein A/G agarose
according to instructions of the manufacturer (Santa
Cruz). > 99.9% of the haptocorrin was removed, as con-
trolled by ELISA and by measurement of UB12BC. Milk
with and without haptocorrin was used without further
dilution. The samples were stored at -20°C until use.
Haptocorrin
Porcine holo-haptocorrin (saturated with vitamin B12)
purified from gastric extracts [20] was employed. The
protein was diluted in 5 mM phosphate buffer pH 7 to a
final concentration of 250 nM. Human haptocorrin unsa-
turated with vitamin B12 was purified from human
donor milk essentially as described previously [21]. The
milk originated from a complete lactation from one
donor. In brief, 100 mL milk was absorbed to 12 mL vita-
min B12-sepharose at room temperature with gentle agi-
tation over night. Subsequently, the B12-sepharose was
applied to a glass column. After washing with 500 mL
50 mM Tris-HCl pH 7, 150 mL 50 mM TrisHCl with
0.5 M NaCl pH 7, and 100 mL H2O, the absorbed hapto-
corrin was eluted with 3 × 20 mL 5 M guanidine-HCl
each eluted during 20-30 min. The eluates were pooled
and dialysed against excess demineralised H2Of o r>4 8h
at 4°C. After lyophilization, the protein was redissolved in
5 mM phosphate buffer pH 7 to a final haptocorrin con-
centration of 250 nM as determined by ELISA, and as
judged by UB12BC analysis, > 97% occurred as unsatu-
rated haptocorrin. All haptocorrin samples were filter
sterilized (0.22 μm) and stored at -20°C prior to use.
Bacterial strains and growth media
The 34 selected bacterial strains (Table 1) are either
commensal in the stomach or intestine and among the
first colonizing bacteria in infants, or are probiotic or
pathogenic strains that infants are commonly exposed to
[22-26]. The selected strains include 3 listeria, 12
escherichia (11 enteropathogenic species), 7 Salmonella
strains, 3 bifidobacteria, 2 lactobacilli, 1 Clostridium,2
staphylococci, 2 enterococci, and 2 streptococci. Lacto-
bacilli were cultivated in de Man, Rogosa, Sharpe (MRS)
bouillon media, and for well-diffusion assay grown on
MRS agar media. Clostridium difficile were cultivated in
a specific liquid medium (CM81, supplied by Oxoid)
and for well-diffussion assay grown on a specific agar
medium (Agar Base CM601 with agar supplement SR96,
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Page 2 of 6Table 1 Effect of human milk, haptocorrin free human milk, apo-haptocorrin and holo-haptocorrin on the growth of
selected bacterial strains
Species Strain and source
[reference]
a, b, c, d
Human milk Haptocorrin free human milk
g Apo-haptocorrin
h Holo-haptocorrin
i
Bifidobacterium breve DSM no 20091 +- NE
Bifidobacterium infantis DSM no 20088 NE NE NE
Bifidobacterium bifidum DSM no 20215 + NE NE
Lactobacillus acidophilus DSM no 20079 + NE NE
Lactobacillus johnsonii DSM no 10533 + NE NE
Clostridium difficile DSM no 1296 NE NE NE
Staphylococcus epidermidis DSM no 20044 + NE NE
Staphylococcus aureus ATCC 29213 NE NE NE
Enterococcus faecalis ATCC 29212 NE NE NE
Enterococcus faecium CCUG 542 T NE NE NE
Streptococcus thermophilus E2; Tosi et al
f -- NE NE
Streptococcus agalactiae CCUG 4208 T NE NE NE
Escherichia coli ATCC 35218 NE NE NE
Escherichia coli O157, wild type
e NE NE NE
Escherichia coli O103:H2, wild type
e + NE NE
Escherichia coli O26:H11, wild type
e NE NE NE
Escherichia coli O145:H
-, wild type
e + NE NE
Escherichia coli O26:H
-, wild type
e NE NE NE
Escherichia coli O126:H20, wild type
e NE NE NE
Escherichia coli O128ab:H
-, wild type
e + NE NE
Escherichia coli O128ab:H2 (1), wild
type
e
+ NE NE
Escherichia coli O128ab:H2 (2), wild
type
e
+ NE NE
Escherichia coli O111:H
-, wild type
e + NE NE
Escherichia coli O127a:H
-; DSM no
8702
+ NE NE
Listeria monocytogenes LO28; -- NE NE
Listeria monocytogenes 4446; Larsen et al,
2002
f
-- NE NE
Listeria monocytogenes 7291; Larsen et al,
2002
f
-- NE NE
Salmonella Infantis (1), wild type
e NE NE NE
Salmonella Infantis (2), wild type
e NE NE NE
Salmonella
Enteritidis
(1), wild type
e + NE NE
Salmonella
Enteritidis
(2), wild type
e + NE NE
Salmonella Typhimurium DT104 NE NE NE
Salmonella Typhimurium DT120 NE NE NE
Salmonella Typhimurium SL1344 NE NE NE
Effect of human milk, haptocorrin free human milk, unsaturated human haptocorrin (250 nM), and saturated porcine haptocorrin (250 nM) respectively, assessed
by comparing the growth in corresponding well-diffusion assays with growth in well-diffusion assays with added phosphate buffer (negative control) and added
erythromycin (positive control). The results represent three independent experiments giving the same result.
+ indicates increased growth, e.g. increased density of bacteria around the wells (as compared to buffer control)
-indicates visible inhibition (minimum 5 mm clearance zone)
NE: No effect
a Number in parentheses refers to different isolates.
b All DSM strains were obtained from the German Collection of Microorganisms and Cell Cultures.
c All ATCC strains were obtained from the American Type Culture Collection.
d All CCUG strains were obtained from the Culture Collection, University of Göteborg.
e Isolated by the National Food Institute, Denmark.
f Source of strain.
g Assays with addition of haptocorrin free human milk were only conducted for strains inhibited by human milk.
h Apo-haptocorrin was derived from human milk.
i Holo-haptocorrin was derived from porcine gastric juice.
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Page 3 of 6supplied by Oxoid). All other bacteria were cultivated
in Brain Heart Infusion (BHI) bouillon media and for
well-diffusion assay grown on BHI agar medium. Bifido-
bacteria, lactobacilli and Clostridium difficile were anae-
robically incubated for 48 hours, while the rest of the
bacteria were aerobically incubated at 24 hours. All
strains were incubated at 37°C.
Well-diffusion assays
The applied well-diffusion assay, which previously has
proven useful to screen for bacteriocin activity [27], is
suitable when only small amounts of samples are avail-
able, and sufficiently sensitive to reveal effects of biolo-
gical relevance. The assay was a modification of the
procedure described by Fuente-Salcido et al.
BHI, MRS or specific Clostridium difficile media with
agar (2%) was melted and tempered to 50°C. One single
cell colony was suspended in 1 mL of the corresponding
bouillon (MRS, BHI or a specific Clostridium difficile
liquid media (CM81)) and mixed with 400 mL agar media,
which was plated in 20 agar plates and allowed to gelati-
nize. A well, 7 mm in diameter, was made in each agar
plate and 20 μL of test sample (human milk, haptocorrin-
free human milk, porcine holo-haptocorrin and human
apo-haptocorrin), 20 μgm L
-1 erythromycin (positive con-
trol for inhibition) or 5 mM phosphate buffer pH 7 (nega-
tive control for inhibition) was added into the well. Only
strains inhibited by human milk were subsequently tested
with haptocorrin-free human milk. Plates were incubated
as described above observing possible inhibition zones. An
inhibition zone of minimally 5 mm was defined as a posi-
tive inhibitory effect. Assays were performed in triplicates.
Results
Media characteristics
BHI media contained 0.13 nM UB12BC and 0.05 nM
vitamin B12, whereas the MRS media contained 0.12 nM
UB12BC and 0.44 nM vitamin B12, which is concentra-
tions well below the concentration of added haptocorrin
(250 nM). Therefore, it seems highly unlikely that the
vitamin B12 content and the UB12BC of the media could
influence our results, respectively by saturating apo-hap-
tocorrin or taking over haptocorrin’s role in vitamin B12
binding.
Effect of human milk with and without haptocorrin
The positive control (erythromycin) and the negative con-
trol (phosphate buffer) gave the expected results for all 34
strains tested; the positive control caused an inhibition
zone around the wells, while the negative control did not.
Human milk inhibited growth of S. thermophilus and
t h ep a t h o g e n i cs t r a i n sL. monocytogenes L028, L. mono-
cytogenes 4446 and L. monocytogenes 7291 (Table 1).
However, this inhibition was not caused by haptocorrin,
since haptocorrin free human milk gave the same result.
In some cases, a visible increased density of the bac-
teria appeared around the wells, when compared to the
growth around the wells only containing buffer. This is
indicated as ‘increased growth’ in Table 1, and was
observed around the wells after addition of human milk
for Bifidobacterium breve, B. bifidum, Lactobacillus
acidophilus, L. johnsonii, Staphylococcus epidermidis,
E. coli O103:H2, E. coli O145:H
-, E. coli O128ab:H
-,
E. coli 128ab:H2(1), E. coli 128ab:H2(2), E. coli O111:H
-,
E. coli O127a:H
-, Salmonella Enteritidis (1) and S. Enter-
itidis (2).
Effect of saturated and unsaturated haptocorrin
Due to limited amounts of human milk derived haptocor-
rin, available porcine haptocorrin was employed for stu-
dies on the effect of the saturated form of the protein.
Addition of porcine holo-haptocorrin in the well-diffusion
assay showed no inhibition of any of the bacteria. Unsatu-
rated human haptocorrin caused an inhibition for B. breve,
but not for any of the other bacteria.
Discussion
In the well-diffusion assay originally developed for assess-
ment of bacteriocin activity, [27], human milk inhibited
growth of S. thermophilus and the pathogenic strains
L. monocytogenes LO28, L. monocytogenes 4446 and
L. monocytogenes 7291. For the latter three, this is consis-
tent with the findings of Lopez-Exposito and coworkers,
who ascribed the inhibitory effect to the lysozyme in
human milk, possibly in combination with lactoferrin/
immunoglobulin A [28]. We were surprised to see an inhi-
bitory effect of human milk on S. thermophilus,a st h i s
species is widely used in the dairy industry [29], but also
this is likely to be attributed to lysozyme/lactoferrin/
immunoglobulin A or other antibacterial proteins in
human milk [30]. Our experiments with haptocorrin-free
human milk revealed that the observed inhibitory effect of
human milk on the mentioned bacteria was not caused by
haptocorrin, because similar inhibition zones were
observed for haptocorrin-free human milk as for human
milk with haptocorrin. In addition, no inhibitory effect
was observed with either purified porcine holo-haptocor-
rin or with human apo-haptocorrin on the given strains.
Human milk caused a higher density of certain bifido-
bacteria, lactobacilli, staphylococci, E. coli and Salmo-
nella strains around the wells. It is well known that
lactic acid bacteria and E. coli strains can ferment lac-
tose present in human milk [31]. More surprisingly,
increased growth was observed for two (non-lactose fer-
menting) Salmonella Enteritidis strains, which may be
ascribed to the oligosaccharide content in human milk.
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corrin on any of the tested bacterial strains was
observed. A study by Adkins & Lönnerdal has shown
inhibitory effect of porcine apo-and holo-haptocorrin on
the growth of a specific enteropathogenic E. coli (EPEC)
strain [10]. However, our results suggest that such an
inhibitory effect is not general towards all EPEC strains.
We tested 11 EPEC strains with porcine holo-haptocor-
rin and did not observe inhibition of the proliferation of
any of these bacteria.
It has previously been suggested that the inhibitory
effect of human haptocorrin on bacterial growth depends
on saturation with vitamin B12, and that only apo-hapto-
corrin exhibits inhibitory effects [8]. The inhibitory effect
of haptocorrin on bacteria may therefore be a matter of
absence of vitamin B12 dependence of the strains.
Unsaturated haptocorrin purified from human milk
inhibited the growth of a single strain (B. breve)o ft h e3 4
included strains. This was highly surprising, since
B. breve is known to be one of the most common bacteria
in the gut of breastfed infants [32]. The inhibitory effect
was not observed with saturated porcine haptocorrin.
This implies that the degree of saturation affects the inhi-
bitory activity of haptocorrin on bacteria, as suggested by
Samson et al [8]. Alternatively, the origin of protein isola-
tion (human or porcine) may influence the effect of hap-
tocorrin since the amino acid sequence and the degree of
glycosylation varies depending on isolation species [33],
but further studies are required to elucidate this.
In spite of the observed effect on B. breve,o u rr e s u l t s
suggest that haptocorrin does not have a general anti-
bacterial effect, and thereby contradict the existing
hypothesis implicating such an effect [1,7,10,15]. There-
fore, we find it unlikely that haptocorrin present in
human milk through inhibitory properties alter the com-
position of the first colonizing bacteria in the intestine
of breastfed infants.
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